Salud financiera de hoja de balance de Amphastar Pharmaceuticals
Salud financiera controles de criterios 3/6
Amphastar Pharmaceuticals tiene un patrimonio de accionistas total de $727.7M y una deuda total de $596.2M, lo que sitúa su ratio deuda-patrimonio en 81.9%. Sus activos y pasivos totales son $1.5B y $817.5M respectivamente. El BAIT de Amphastar Pharmaceuticals es de $214.3M, por lo que su ratio de cobertura de intereses es de 7.9. Tiene efectivo e inversiones a corto plazo que ascienden a $250.5M.
Información clave
81.9%
Ratio deuda-patrimonio
US$596.21m
Deuda
| Ratio de cobertura de intereses | 7.9x |
| Efectivo | US$250.49m |
| Patrimonio | US$727.68m |
| Total pasivo | US$817.50m |
| Activos totales | US$1.55b |
Actualizaciones recientes sobre salud financiera
Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
Aug 27
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Recent updates
Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)
Oct 25Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Sep 15Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines
Sep 12Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
Aug 27Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 05Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Jul 01Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
May 30Amphastar Pharmaceuticals: Buy When Fear Is Overblown
May 30Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($545.9M) de AMPH superan a sus pasivos a corto plazo ($159.0M).
Pasivo a largo plazo: Los activos a corto plazo ($545.9M) de AMPH no cubren sus pasivos a largo plazo ($658.5M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de AMPH (47.5%) se considera alta.
Reducción de la deuda: El ratio deuda-patrimonio de AMPH ha crecido de 10.2% a 81.9% en los últimos 5 años.
Cobertura de la deuda: La deuda de AMPH está bien cubierta por el flujo de caja operativo (34.9%).
Cobertura de intereses: Los pagos de intereses de la deuda de AMPH están bien cubiertos por el BAIT (7.9x cobertura).